Long Term Survival of a Patient with Metastatic Renal Cell Carcinoma Treated with Half-Dose Pazopanib: A Case Report

We describe the case of a 59-year-old woman who underwent a radical left nephrectomy for renal cell cancer in 1993. After 7 years, the disease relapsed as thyroid and pulmonary metastases and she has been initially treated with chemotherapy. At further progression we administered an antiangiogenic drug, Sunitinib for 9 months then we switched to Pazopanib. The patient is still receiving a half-dose of Pazopanib (46 months) and she is showing a longlasting response with an optimal safety profile. In this patient, Pazopanib demonstrated a significant improvement in PFS and tumor response also with half a dose. Nephrectomy, metastasectomy, medical therapy and targeted treatments have been shown able to prolong survival and improve quality of life. This is an example of chronicized disease in a patient who can be defined as a long-term survivor.